Business Wire | Aug 18, 2020 11:01AM EDT

Defiance ETFs Surpasses $500 Million in AUM

Aug. 18, 2020

NEW YORK--(BUSINESS WIRE)--Aug. 18, 2020--Today, Defiance ETFs announced it has surpassed $500 million in assets under management (AUM).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200818005587/en/

FIVG The 5G ETF (Graphic: Business Wire)

"Despite a global pandemic that has generated uncertainties across many sectors, we have continued to bring innovative first-to-market ETFs that are in high demand by both retail and institutional investors," said Matthew Bielski, Chief Executive Officer at Defiance ETFs.

On August 4, 2020 Defiance ETFs launched the Junior Biotech ETF (IBBJ) to complement its flagship 5G ETF (FIVG) and Computing ETF (QTUM). For additional information, please visit www.DefianceETFs.com or call 1-833-333-9383.

AUM as of August 12th 2020

The Fund's investment objectives, risks, charges, and expenses must be considered carefully before investing. The prospectus and summary prospectus contain this and other important information about the investment company. The prospectus can be obtained by calling 1-833-333-9383 Please read it carefully before investing.

Investing involves risk. Principal loss is possible. The Fund is a recently organized investment company with no operating history. The securities of small-capitalization companies may be more vulnerable to adverse issuer, market, political, or economic developments than securities of large- or mid-capitalization companies. The success of biotechnology companies is highly dependent on the development, procurement and/or marketing of drugs. The values of biotechnology companies are also dependent on the development, protection and exploitation of intellectual property rights and other proprietary information, and the profitability of biotechnology companies may be affected significantly by such things as the expiration of patents or the loss of, or the inability to enforce, intellectual property rights. The research and development and other costs associated with developing or procuring new drugs, products or technologies and the related intellectual property rights can be significant, and the results of such research and expenditures are unpredictable and may not necessarily lead to commercially successful products.

A commission may apply when buying or selling an ETF.

Defiance ETFs are distributed by Foreside Fund Services, LLC.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200818005587/en/

CONTACT: Julia Stoll MacMillan Communications 1-833-333-9393 julia@macmillancom.com